ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc (ACXP)

1,39
0,00
( 0,00% )
Aktualisiert: 16:28:14

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
1,39
Gebot
1,36
Fragen
1,39
Volumen
133.963
1,3101 Tagesbereich 1,47
1,18 52-Wochen-Bereich 5,28
Marktkapitalisierung
Handelsende
1,39
Handelsbeginn
1,47
Letzte Trade
3
@
1.3615
Letzter Handelszeitpunkt
16:30:02
Finanzvolumen
US$ 190.448
VWAP
1,4216
Durchschnittliches Volumen (3 Mio.)
61.432
Ausgegebene Aktien
16.892.548
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,56
Gewinn pro Aktie (EPS)
-0,86
Erlöse
-
Nettogewinn
-14,58M

Über Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Acurx Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACXP. The last closing price for Acurx Pharmaceuticals was US$1,39. Over the last year, Acurx Pharmaceuticals shares have traded in a share price range of US$ 1,18 to US$ 5,28.

Acurx Pharmaceuticals currently has 16.892.548 shares in issue. The market capitalisation of Acurx Pharmaceuticals is US$23,48 million. Acurx Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.56.

ACXP Neueste Nachrichten

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset PR Newswire STATEN ISLAND, N.Y., Nov. 20, 2024 STATEN ISLAND, N.Y., Nov. 20, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc...

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y., Nov. 13, 2024 STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx...

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference PR Newswire STATEN ISLAND, N.Y., Oct. 21, 2024 The...

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement PR Newswire STATEN ISLAND, N.Y...

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 PR Newswire STATEN ISLAND, N.Y., Oct. 16, 2024 STATEN ISLAND, N.Y., Oct. 16, 2024 /PRNewswire/ -- Acurx...

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues PR Newswire STATEN ISLAND, N.Y., Sept. 26, 2024 New analyses...

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium PR Newswire STATEN...

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted business TV show, announces episode 591, airing on the Fox Business Network tonight, Monday...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.43-23.62637362641.821.851.182576221.44461567CS
4-0.49-26.06382978721.881.961.18885111.55871676CS
12-0.79-36.23853211012.182.2451.18614321.79152184CS
26-0.84-37.6681614352.233.3251.18612402.09742973CS
52-2.25-61.81318681323.645.281.181096943.0946889CS
156-3.44-71.22153209114.838.821.171157293.31298608CS
260-4.56-76.63865546225.958.821.171416474.20132859CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
WORXSCWorx Corporation
US$ 2,15
(119,39%)
91,33M
SKKSKK Holdings Limited
US$ 9,95
(118,20%)
4,11M
CRNCCerence Inc
US$ 4,87
(72,70%)
17,99M
SURGSurgePays Inc
US$ 2,4249
(66,09%)
4,16M
SPAISafe Pro Group Inc
US$ 4,52
(41,25%)
36,61M
PYXSPyxis Oncology Inc
US$ 2,095
(-45,16%)
7,42M
KURAKura Oncology Inc
US$ 10,035
(-36,93%)
6,46M
SHOTWSafety Shot Inc
US$ 0,1001
(-33,27%)
2,5k
BLRXBioLineRx Ltd
US$ 0,3651
(-33,03%)
4,79M
AGFYAgrify Corporation
US$ 26,9076
(-30,58%)
290,85k
CDTConduit Pharmaceuticals Inc
US$ 0,12299
(33,25%)
441,18M
AKTSAkoustis Technologies Inc
US$ 0,1018
(16,88%)
169,89M
NVDANVIDIA Corporation
US$ 142,65
(-2,22%)
153,07M
WORXSCWorx Corporation
US$ 2,14
(118,37%)
91,41M
ELABElevai Labs Inc
US$ 0,02035
(-4,91%)
90,08M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock